Claims

~~[Claim 1] A therapeutic method for an OX40-related immune- or allergy-related disease including subcutaneously administering an anti-OX40 antibody to a patient at a dose of 150 mg to 600 mg once in two weeks to four weeks for at least 16 weeks.~~

~~[Claim 2] The therapeutic method according to claim 1, wherein the anti-OX40 antibody is a monoclonal antibody containing a heavy chain variable region (also called VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (also called VL) containing the amino acid sequence of SEQ ID NO: 2.~~

~~[Claim 3] The therapeutic method according to claim 1, wherein the administration is continued for at least 20 weeks, 22 weeks, 24 weeks or 34 weeks after starting the administration.~~

~~[Claim 4] The therapeutic method according to claim 1, wherein the OX40-related immune- or allergy-related disease is atopic dermatitis.~~

~~[Claim 5] The therapeutic method according to claim 1, wherein the anti-OX40 antibody is subcutaneously administered once in two weeks, three weeks or four weeks.~~

~~[Claim 6] The therapeutic method according to claim 1, wherein the dose is selected from 150 mg, 300 mg, 450 mg and 600 mg.~~

~~[Claim 7] The therapeutic method according to claim 1, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis.~~

~~[Claim 8] The therapeutic method according to claim 1, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis which is poorly controllable using a topical agent or moderate to severe atopic dermatitis for which a topical therapy is not medically recommended.~~

~~[Claim 9] The therapeutic method according to claim 1 which is combined with a known topical agent such as a steroid.~~

~~[Claim 10] The therapeutic method according to claim 1, wherein the anti-OX40 antibody is KHK4083.~~

~~[Claim 11] A therapeutic method for an OX40-related immune- or allergy-related disease including subcutaneously administering an anti-OX40 antibody to a patient at a dose of 150 mg to 600 mg once in two weeks to four weeks continuously at the same dose.~~

~~[Claim 12] The therapeutic method according to claim 11, wherein the anti-OX40~~

~~antibody is a monoclonal antibody containing a heavy chain variable region (also called VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (also called VL) containing the amino acid sequence of SEQ ID NO: 2.~~

~~[Claim 13] The therapeutic method according to claim 11, wherein the administration is continued for at least 16 weeks, 20 weeks, 22 weeks, 24 weeks or 34 weeks after starting the administration.~~

~~[Claim 14] The therapeutic method according to claim 11, wherein the OX40-related immune- or allergy-related disease is atopic dermatitis.~~

~~[Claim 15] The therapeutic method according to claim 11, wherein the anti-OX40 antibody is subcutaneously administered once in two weeks, three weeks or four weeks.~~

~~[Claim 16] The therapeutic method according to claim 11, wherein the dose is selected from 150 mg, 300 mg, 450 mg and 600 mg.~~

~~[Claim 17] The therapeutic method according to claim 11, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis.~~

~~[Claim 18] The therapeutic method according to claim 11, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis which is poorly controllable using a topical agent or moderate to severe atopic dermatitis for which a topical therapy is not medically recommended.~~

~~[Claim 19] The therapeutic method according to claim 11 which is combined with a known topical agent such as a steroid.~~

~~[Claim 20] The therapeutic method according to claim 11, wherein the anti-OX40 antibody is KHK4083.~~

[Claim ~~2~~1] Use of an anti-OX40 antibody ~~A composition for use in~~ in the manufacture of a composition for the treatment of an OX40-related immune- or allergy-related disease, wherein the anti-OX40 antibody is to be subcutaneously administered to a patient at a dose of 150 mg to 600 mg once in two weeks to four weeks for at least 16 weeks.

[Claim ~~2~~2] The ~~composition for~~ use according to claim ~~2~~1, wherein the anti-OX40 antibody is a monoclonal antibody containing a heavy chain variable region (also called VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (also called VL) containing the amino acid sequence of SEQ ID NO: 2.

[Claim ~~2~~3] The ~~composition for~~ use according to claim ~~2~~1 or ~~2~~2, wherein the administration is to be continued for at least 20 weeks, 22 weeks, 24 weeks

or 34 weeks after starting the administration.

[Claim ~~2~~4] The ~~composition for~~ use according to claim ~~2~~1, wherein the OX40-related immune- or allergy-related disease is atopic dermatitis.

[Claim ~~2~~5] The ~~composition for~~ use according to any of claims ~~2~~1-~~2~~4, wherein the anti-OX40 antibody is to be subcutaneously administered once in two weeks, three weeks or four weeks.

[Claim ~~2~~6] The ~~composition for~~ use according to any of claims ~~2~~1-~~2~~5, wherein the dose is selected from 150 mg, 300 mg, 450 mg and 600 mg.

[Claim ~~2~~7] The ~~composition for~~ use according to any of claim ~~2~~1, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis.

[Claim ~~2~~8] The ~~composition for~~ use according to claim ~~2~~1, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis which is poorly controllable using a topical agent or moderate to severe atopic dermatitis for which a topical therapy is not medically recommended.

[Claim ~~2~~9] The ~~composition for~~ use according to any of claims ~~2~~1-~~2~~8 which is combined with a known topical agent such as a steroid.

[Claim ~~3~~10] The ~~composition for~~ use according to any of claims ~~2~~1-~~2~~9, wherein the anti-OX40 antibody is KHK4083.

[Claim ~~3~~11] Use of an anti-OX40 antibody ~~A composition for use in~~ in the manufacture of a medicament for the treatments of an OX40-related immune- or allergy-related disease, wherein an anti-OX40 antibody is to be subcutaneously administered~~ing~~ to a patient at a dose of 150 mg to 600 mg once in two weeks to four weeks continuously at the same dose.

[Claim ~~3~~12] The ~~composition for~~ use according to claim ~~3~~11, wherein the anti-OX40 antibody is a monoclonal antibody containing a heavy chain variable region (also called VH) containing the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (also called VL) containing the amino acid sequence of SEQ ID NO: 2.

[Claim ~~3~~13] The ~~composition for~~ use according to claim ~~3~~11 or ~~3~~12, wherein the administration is to be continued for at least 16 weeks, 20 weeks, 22 weeks, 24 weeks or 34 weeks after starting the administration.

[Claim ~~3~~14] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~13, wherein the OX40-related immune- or allergy-related disease is atopic dermatitis.

[Claim ~~3~~15] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~14, wherein the anti-OX40 antibody is to be subcutaneously administered once in two

weeks, three weeks or four weeks.

[Claim ~~3~~16] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~15, wherein the dose is selected from 150 mg, 300 mg, 450 mg and 600 mg.

[Claim ~~3~~17] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~16, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis.

[Claim ~~3~~18] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~17, wherein the OX40-related immune- or allergy-related disease is moderate to severe atopic dermatitis which is poorly controllable using a topical agent or moderate to severe atopic dermatitis for which a topical therapy is not medically recommended.

[Claim ~~3~~19] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~18, which is combined with a known topical agent such as a steroid.

[Claim ~~4~~20] The ~~composition for~~ use according to any of claims ~~3~~11-~~3~~19, wherein the anti-OX40 antibody is KHK4083.